Quark Pharmaceuticals Inc:製薬・医療:M&Aディール及び事業提携情報

◆英語タイトル:Quark Pharmaceuticals Inc - Pharmaceuticals & Healthcare - Deals and Alliances Profile
◆商品コード:DATA904C5159
◆発行会社(調査会社):GlobalData
◆発行日:2018年9月
◆ページ数:24
◆レポート言語:英語
◆レポート形式:PDF
◆納品方法:Eメール
◆対象地域:アメリカ
◆産業分野:製薬・医療
◆販売価格オプション(消費税別)
Single User(1名様閲覧用)USD250 ⇒換算¥37,000見積依頼/購入/質問フォーム
Site License(同一事業所内共有可)USD500 ⇒換算¥74,000見積依頼/購入/質問フォーム
Enterprisewide License(複数事業所内共有可)USD750 ⇒換算¥111,000見積依頼/購入/質問フォーム
販売価格オプションの説明はこちらでご利用ガイドはこちらでご確認いただけます。
※お支払金額は「換算金額(日本円)+消費税+配送料(Eメール納品は無料)」です。
※本体価格が¥30,000未満のレポートにつきましては、ハンドリングチャージ¥5,000が別途かかります。
※Eメールによる納品の場合、通常ご注文当日〜2日以内に納品致します。
※レポート納品後、納品日+5日以内に請求書を発行し、お客様宛に郵送しますので、請求書発行日より2ヶ月以内に振込をお願いします。
※為替レートは適宜修正・更新しております。リアルタイム更新ではありません。
※弊社H&Iグローバルリサーチ株式会社はGlobalData社の日本における正規販売代理店です。同社発行の企業調査レポートに関するお問い合わせは弊社までお願い致します。
GlobalData社の概要はこちらでご確認いただけます。



【レポートの概要】

Summary
Quark Pharmaceuticals Inc (Quark), a subsidiary of SBI Biotech Co Ltd, is a clinical-stage pharmaceutical company in the development of novel RNAi-based therapeutics. It offers under development products which include PF-655, a synthetic siRNA which is used for the treatment of diabetic macular edema and age-related macular degeneration; and QPI-1002, a synthetic siRNA which is designed for the treatment of acute kidney injury and delayed graft function. The company also provides QPI-1007, a synthetic siRNA which is used for the treatment of ocular neuroprotection and non-arteritic anterior ischemic optic neuropathy. Quark offers its products for multiple unmet medical needs. It works in collaboration with many other companies across the world on its products and technologies. The company has operations in Israel and the US. Quark is headquartered in Fremont, California, the US.

Quark Pharmaceuticals Inc – Pharmaceuticals & Healthcare – Deals and Alliances Profile provides you comprehensive data and trend analysis of the company’s Mergers and Acquisitions (M&As), partnerships and financings. The report provides detailed information on Mergers and Acquisitions, Equity/Debt Offerings, Private Equity, Venture Financing and Partnership transactions recorded by the company over a five year period. The report offers detailed comparative data on the number of deals and their value categorized into deal types, sub-sector and regions.

GlobalData derived the data presented in this report from proprietary in-house Pharma eTrack deals database, and primary and secondary research.

Scope

- Financial Deals – Analysis of the company’s financial deals including Mergers and Acquisitions, Equity/Debt Offerings, Private Equity, Venture Financing and Partnerships.
- Deals by Year – Chart and table displaying information encompassing the number of deals and value reported by the company by year, for a five year period.
- Deals by Type – Chart and table depicting information including the number of deals and value reported by the company by type such as Mergers and Acquisitions, Equity/Debt Offering etc.
- Deals by Region – Chart and table presenting information on the number of deals and value reported by the company by region, which includes North America, Europe, Asia Pacific, the Middle East and Africa and South and Central America.
- Deals by Sub-sector – Chart and table showing information on the number of deals and value reported by the company, by sub-sector.
- Major Deals – Information on the company’s major financial deals. Each such deal has a brief summary, deal type, deal rationale; and deal financials and target Company’s (major public companies) key financial metrics and ratios.
- Business Description – A brief description of the company’s operations.
- Key Employees – A list of the key executives of the company.
- Important Locations and Subsidiaries – A list and contact details of key centers of operation and subsidiaries of the company.
- Key Competitors – A list of the key competitors of the company.
- Key Recent Developments – A brief on recent news about the company.

Reasons to Buy

Get detailed information on the company’s financial deals that enable you to understand the company’s expansion/divestiture and fund requirements
- The profile enables you to analyze the company’s financial deals by region, by year, by business segments and by type, for a five year period.

Understand the company’s business segments’ expansion / divestiture strategy
- The profile presents deals from the company’s core business segments’ perspective to help you understand its corporate strategy.

Access elaborate information on the company’s recent financial deals that enable you to understand the key deals which have shaped the company
- Detailed information on major recent deals includes a summary of each deal, deal type, deal rationale, deal financials and Target Company’s key financial metrics and ratios.

Equip yourself with detailed information about the company’s operations to identify potential customers and suppliers.
- The profile analyzes the company’s business structure, locations and subsidiaries, key executives and key competitors.

Stay up-to-date on the major developments affecting the company
- Recent developments concerning the company presented in the profile help you track important events.

Gain key insights into the company for academic or business research
- Key elements such as break up of deals into categories and information on detailed major deals are incorporated into the profile to assist your academic or business research needs.

Note*: Some sections may be missing if data is unavailable for the company.

【レポートの目次】

Table of Contents
Table of Contents 3
List of Tables 4
List of Figures 4
Quark Pharmaceuticals Inc, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 5
Quark Pharmaceuticals Inc, Pharmaceuticals & Healthcare Deals By Type, 2012 to YTD 2018 6
Quark Pharmaceuticals Inc, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 7
Quark Pharmaceuticals Inc, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2012 to YTD 2018 8
Quark Pharmaceuticals Inc, Medical Devices Deals, 2012 to YTD 2018 9
Quark Pharmaceuticals Inc, Pharmaceuticals & Healthcare, Deals Summary, 2012 to YTD 2018 10
Quark Pharmaceuticals Inc, Pharmaceuticals & Healthcare, Deal Details 11
Partnerships 11
Quark Pharma Enters into Agreement with Transplant Genomics 11
Suzhou Ribo Life Science Forms Joint Venture With Quark Pharma 12
Licensing Agreements 13
Biocon And Quark Pharma Enter Into Agreement To Develop siRNA Based Therapeutics 13
Quark Pharma Amends Licensing Agreement With Pfizer For PF-655 14
Quark Pharmaceuticals Inc – Key Competitors 15
Quark Pharmaceuticals Inc – Key Employees 16
Quark Pharmaceuticals Inc – Locations And Subsidiaries 17
Head Office 17
Other Locations & Subsidiaries 17
Joint Venture 17
Recent Developments 18
Product News 18
11/13/2017: RiboQuark Pharmaceutical Technology Announces Enrollment of The First Ever Patient in China for a Pivotal Clinical Trial with a siRNA Drug Candidate as Part of a Global Clinical Study of the Ocular Neuroprotectant QPI-1007 18
Clinical Trials 20
Nov 07, 2017: Quark Pharmaceuticals to Present Positive Phase 2 Efficacy And Safety Results Of QPI-1002, A siRNA Targeting p53, For Prevention Of Acute Kidney Injury Following Cardiac Surgery, at the EuroTIDES Conference 20
Nov 04, 2017: Quark Pharmaceuticals Presents Results from a Positive Phase 2 Study of QPI-1002 for Prevention of Acute Kidney Injury Following Cardiac Surgery at the American Society of Nephrology Meeting 21
Nov 01, 2017: Quark Pharmaceuticals Phase 2 Data on the Efficacy and Safety of QPI-1002 for Prevention of Acute Kidney Injury Following Cardiac Surgery to Be Presented at the American Society of Nephrology Meeting 22
Jul 27, 2017: Quark Pharmaceuticals Reports Positive Results from a Phase 2 Study to Evaluate the Efficacy and Safety of QPI-1002 for the Prevention of Acute Kidney Injury (AKI) in Subjects at High Risk of AKI Following Cardiac Surgery 23
Appendix 24
Methodology 24
About GlobalData 24
Contact Us 24
Disclaimer 24

List of Tables
Quark Pharmaceuticals Inc, Pharmaceuticals & Healthcare, Key Facts 2
Quark Pharmaceuticals Inc, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 5
Quark Pharmaceuticals Inc, Pharmaceuticals & Healthcare Deals By Type, 2012 to YTD 2018 6
Quark Pharmaceuticals Inc, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 7
Quark Pharmaceuticals Inc, Deals By Therapy Area, 2012 to YTD 2018 8
Quark Pharmaceuticals Inc, Medical Devices Deals, 2012 to YTD 2018 9
Quark Pharmaceuticals Inc, Pharmaceuticals & Healthcare, Deals Summary, 2012 to YTD 2018 10
Quark Pharma Enters into Agreement with Transplant Genomics 11
Suzhou Ribo Life Science Forms Joint Venture With Quark Pharma 12
Biocon And Quark Pharma Enter Into Agreement To Develop siRNA Based Therapeutics 13
Quark Pharma Amends Licensing Agreement With Pfizer For PF-655 14
Quark Pharmaceuticals Inc, Key Competitors 15
Quark Pharmaceuticals Inc, Key Employees 16
Quark Pharmaceuticals Inc, Subsidiaries 17
Quark Pharmaceuticals Inc, Joint Venture 17

List of Figures
Quark Pharmaceuticals Inc, Pharmaceuticals & Healthcare, Deals by Type, 2012 to YTD 2018 2
Quark Pharmaceuticals Inc, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 2
Quark Pharmaceuticals Inc, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 2
Quark Pharmaceuticals Inc, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2012 to YTD 2018 2
Quark Pharmaceuticals Inc, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 5
Quark Pharmaceuticals Inc, Pharmaceuticals & Healthcare, Deals by Type, 2012 to YTD 2018 6
Quark Pharmaceuticals Inc, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 7
Quark Pharmaceuticals Inc, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2012 to YTD 2018 8
Quark Pharmaceuticals Inc, Medical Devices Deals, 2012 to YTD 2018 9

★海外企業調査レポート[Quark Pharmaceuticals Inc:製薬・医療:M&Aディール及び事業提携情報]についてメールでお問い合わせはこちら

■おすすめ企業レポート■
  • Compagnie Generale des Etablissements Michelin:企業の戦略・SWOT・財務分析
    Compagnie Generale des Etablissements Michelin - Strategy, SWOT and Corporate Finance Report Summary Compagnie Generale des Etablissements Michelin - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, ope …
  • Bioton SA (BIO):企業の戦略的SWOT分析
    Bioton SA (BIO) - Strategic SWOT Analysis Review provides a comprehensive insight into the company’s history, corporate strategy, business structure and operations. The report contains a detailed SWOT analysis, information on the company’s key employees, key competitors and major products and servic …
  • Rabobank Group:企業のM&A・事業提携・投資動向
    Rabobank Group - Mergers & Acquisitions (M&A), Partnerships & Alliances and Investment Report Summary Marketline's Rabobank Group Mergers & Acquisitions (M&A), Partnerships & Alliances and Investments report includes business description, detailed reports on mergers and acquisitions (M&A), divestmen …
  • Sun Pharma Advanced Research Company Ltd (SPARC):企業の財務・戦略的SWOT分析
    Summary Sun Pharma Advanced Research Company Ltd (SPARC), a subsidiary of Sun Pharmaceutical Industries Ltd, is a bio pharmaceutical clinical research and development service provider. The company develops active pharmaceutical ingredients, formulations and drug delivery technologies for the treatme …
  • MOL Hungarian Oil and Gas Plc (MOL):企業の財務・戦略的SWOT分析
    MOL Hungarian Oil and Gas Plc (MOL) - Financial and Strategic SWOT Analysis Review provides you an in-depth strategic SWOT analysis of the company’s businesses and operations. The profile has been compiled by GlobalData to bring to you a clear and an unbiased view of the company’s key strengths and …
  • Entasis Therapeutics Inc-製薬・医療分野:企業M&A・提携分析
    Summary Entasis Therapeutics Inc (Entasis) discovers and develops anti-infective products for drug-resistant bacterial infections. The company’s pipeline products include ETX2514, a potent inhibitor of class A, C, and D beta-lactamases intended to treat serious gram-negative infections, such as Acin …
  • Poupart Limited:企業の戦略・SWOT・財務情報
    Poupart Limited - Strategy, SWOT and Corporate Finance Report Summary Poupart Limited - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, product and service offerings and corpo …
  • EA Pharma Co Ltd:製薬・医療:M&Aディール及び事業提携情報
    Summary EA Pharma Co Ltd (EA Pharma), formerly Ajinomoto Pharmaceuticals Co Ltd, a subsidiary of Eisai Co Ltd, is a clinical research organization that develops, manufactures and sells pharmaceutical products. The organization develops pharmaceutical products based on amino acid-related technologies …
  • Wilbur-Ellis Holdings Inc:企業の戦略的SWOT分析
    Wilbur-Ellis Holdings Inc - Strategic SWOT Analysis Review provides a comprehensive insight into the company’s history, corporate strategy, business structure and operations. The report contains a detailed SWOT analysis, information on the company’s key employees, key competitors and major products …
  • Continental Resources Inc (CLR):企業の財務・戦略的SWOT分析
    Summary Continental Resources Inc (Continental Resources) is an independent upstream oil and gas company. The company explores for, develops and produces crude oil and natural gas. It operates in the onshore oil field, the Bakken of North Dakota and Montana; SCOOP play in Woodford reservoir; SCOOP S …
  • Mesa Air Group, Inc.:企業の戦略・SWOT・財務分析
    Mesa Air Group, Inc. - Strategy, SWOT and Corporate Finance Report Summary Mesa Air Group, Inc. - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, product and service offerings …
  • Tetra Technologies, Inc.
    Tetra Technologies, Inc. - Strategy, SWOT and Corporate Finance Report Summary Tetra Technologies, Inc. - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, product and service o …
  • Panacea Biotec Ltd (PANACEABIO):製薬・医療:M&Aディール及び事業提携情報
    Summary Panacea Biotec Ltd (Panacea) is a research-based health management company which focuses on manufactures and commercializes pharmaceuticals; biopharmaceuticals; natural, and indigenous products; and vaccines. Its vaccines portfolio includes paediatric vaccines, including trivalent and monova …
  • The Shanghai Commercial & Savings Bank Ltd:企業の戦略・SWOT・財務情報
    The Shanghai Commercial & Savings Bank Ltd - Strategy, SWOT and Corporate Finance Report Summary The Shanghai Commercial & Savings Bank Ltd - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, …
  • Telekom Slovenije, d.d. (TLSG):企業の財務・戦略的SWOT分析
    Telekom Slovenije, d.d. (TLSG) - Financial and Strategic SWOT Analysis Review provides you an in-depth strategic SWOT analysis of the company’s businesses and operations. The profile has been compiled by GlobalData to bring to you a clear and an unbiased view of the company’s key strengths and weakn …
  • Jyske Bank A/S:企業の戦略・SWOT・財務情報
    Jyske Bank A/S - Strategy, SWOT and Corporate Finance Report Summary Jyske Bank A/S - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, product and service offerings and corpora …
  • Aalborg Portland Holding A/S:企業の戦略・SWOT・財務情報
    Aalborg Portland Holding A/S - Strategy, SWOT and Corporate Finance Report Summary Aalborg Portland Holding A/S - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, product and s …
  • Wesfarmers Limited:企業の戦略・SWOT・財務分析
    Wesfarmers Limited - Strategy, SWOT and Corporate Finance Report Summary Wesfarmers Limited - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, product and service offerings and …
  • Scope Metals Group Ltd:企業の戦略・SWOT・財務情報
    Scope Metals Group Ltd - Strategy, SWOT and Corporate Finance Report Summary Scope Metals Group Ltd - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, product and service offer …
  • R-Pharm:製薬・医療:M&Aディール及び事業提携情報
    Summary R-Pharm is a pharmaceutical company that manufactures and markets therapeutic drugs. The company offers drugs in areas of oncology, hematology, cardiology, immunology, and antibacterial and anti-viral diseases. It offers solutions on treatment of HIV-infection, organ transplantation, dissemi …

◆H&Iグローバルリサーチ株式会社のお客様(例)◆